<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        244-334-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEUKAST 4 mg chewable tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LEUKAST Paediatric is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, LEUKAST Paediatric improves asthma symptoms and helps control asthma.</p><p>Your doctor has prescribed LEUKAST Paediatric to treat asthma, preventing your asthma symptoms during the day and night.</p><ul><li>LEUKAST Paediatric is used for the treatment of patients who are not adequately controlled on their medication and need additional therapy.</li><li>LEUKAST Paediatric may also be used as an alternative treatment to inhaled corticosteroids for 6 to 14 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</li><li>LEUKAST Paediatric also helps prevent the narrowing of airways triggered by exercise.</li></ul><p>Your doctor will determine how LEUKAST Paediatric should be used depending on the symptoms and severity of you or your child&rsquo;s asthma.</p><p><strong>What is asthma?</strong></p><p>Asthma is a long-term disease.</p><p>Asthma includes:</p><ul><li>difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</li><li>sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</li><li>swelling (inflammation) in the lining of the airways.</li></ul><p><strong>Symptoms of asthma include: </strong>Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you or your child has now or has had.</p><p><strong>Do not take LEUKAST Paediatric if you or your child</strong></p><ul><li>is allergic (hypersensitive) to montelukast or any of the other ingredients of LEUKAST Paediatric (see 6. Further information).</li></ul><p><strong>Take special care with LEUKAST Paediatric</strong></p><ul><li>If you or your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</li><li>Oral LEUKAST Paediatric is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you or your child. Always have your inhaled rescue medicine for asthma attacks with you.</li><li>It is important that you or your child take all asthma medications prescribed by your doctor. LEUKAST Paediatric should not be used instead of other asthma medica- tions your doctor has prescribed for you or your child.</li><li>Any patient on anti-asthma medicines should be aware that if you develop a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</li><li>You or your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your asthma worse.</li></ul><p><strong>Use in children</strong></p><p>For children 2 to 5 years old, LEUKAST Paediatric 4 mg chewable tablets are available.</p><p>For children 6 to 14 years old, LEUKAST Paediatric 5 mg chewable tablets are available.</p><p><strong>Taking other medicines</strong></p><p>Some medicines may affect how LEUKAST Paediatric works, or LEUKAST Paediatric may affect how other medicines work.</p><p>Please tell your doctor or pharmacist if you or your child is taking or has recently taken other medicines, including those obtained without a prescription.</p><p>Tell your doctor if you or your child is taking the following medicines before starting LEUKAST Paediatric:</p><ul><li>phenobarbital (used for treatment of epilepsy)</li><li>phenytoin (used for treatment of epilepsy)</li><li>rifampicin (used to treat tuberculosis and some other infections)</li></ul><p><strong>Taking LEUKAST Paediatric with food and drink </strong></p><p>LEUKAST Paediatric 4 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Use in pregnancy</p><p>Women who are pregnant or intend to become pregnant should consult their doctor before taking LEUKAST. Your doctor will assess whether you can take LEUKAST during this time.</p><p><strong>Use in breast-feeding</strong></p><p>It is not known if LEUKAST appears in breast milk. You should consult your doctor before taking LEUKAST if you are breast-feeding or intend to breast-feed.</p><p><strong>Driving and using machines</strong></p><p>LEUKAST is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with LEUKAST may affect some patients&rsquo; ability to drive or operate machinery.</p><p><strong>Important information about some of the ingredients of LEUKAST Paediatric</strong></p><p>LEUKAST Paediatric chewable tablets contain aspartame, a source of phenylalanine. If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each LEUKAST Paediatric mg chewable tablet contains phenylalanine (equivalent to 0.96 mg phenylalanine&nbsp;per 4 mg chewable tablet).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>This medicine is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet.</li><li>Your child should take only one tablet of LEUKAST</li></ul><p>Paediatric once a day as prescribed by your doctor.</p><ul><li>It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</li><li>Always have your child take LEUKAST Paediatric as your doctor has told you. You should check with your child&rsquo;s doctor or pharmacist if you are not sure.</li><li>To be taken by mouth</li></ul><p><strong>For children 2 to 5 years of age:</strong></p><p>One LEUKAST Paediatric 4 mg chewable tablet daily to be taken in the evening. LEUKAST Paediatric 4 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p>If your child is taking LEUKAST Paediatric, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.</p><p>For children 2 to 5 years old, LEUKAST Paediatric 4 mg chewable tablets are available.</p><p>For children 6 to 14 years old, LEUKAST Paediatric 5 mg chewable tablets are available. The LEUKAST Paediatric 4 mg chewable tablet is not recommended below 2 years of age.</p><p><strong>If you or your child takes more LEUKAST Paediatric than you should</strong></p><p>Contact your doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p><strong>If you forget to take LEUKAST Paediatric or give LEUKAST Paediatric to your child</strong></p><p>Try to take LEUKAST Paediatric as prescribed. However, if you or your child misses a dose, just resume the usual schedule of one tablet once daily.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you or your child stops taking LEUKAST Paediatric</strong></p><p>LEUKAST Paediatric can treat your child&rsquo;s asthma only if he/she continues taking it.</p><p>It is important for your child to continue taking LEUKAST Paediatric for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p><strong>If you have any further questions on the use of this product, ask your child&rsquo;s doctor or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, LEUKAST Paediatric can cause side effects, although not everybody gets them.</p><p>In clinical studies with LEUKAST Paediatric 5 mg chewable tablets, the most commonly reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be related to LEUKAST Paediatric were:</p><ul><li>headache</li></ul><p>Additionally, the following side effect was reported in clinical studies with LEUKAST 10 mg film-coated tablets:</p><ul><li>abdominal pain</li></ul><p>These were usually mild and occurred at a greater frequency in patients treated with LEUKAST than placebo (a pill containing no medication).</p><p>Additionally, while the medicine has been on the market, the following have been reported:</p><p>Very common side effects (affect more than 1 in 10 people)</p><ul><li>Upper respiratory infection</li></ul><p>Common side effects (affects 1 to 10 patients in 100) include:</p><ul><li>Diarrhoea, nausea, vomiting</li><li>Rash</li><li>Fever</li></ul><p>Uncommon side effects (affects 1 to 10 patients in 1,000) include:</p><ul><li>Allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing</li><li>Behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility, depression</li><li>Dizziness, drowsiness, pins and needles/numbness, seizure</li><li>Nosebleed</li><li>Dry mouth, indigestion</li><li>Bruising, itching, hives</li><li>Joint or muscle pain, muscle cramps</li><li>Weakness/tiredness, feeling unwell, swelling</li></ul><p>Rare side effects (affects 1 to 10 patients in 10,000) include:</p><ul><li>Increased bleeding tendency</li><li>Tremor, disturbance in attention, memory impairment</li><li>Palpitations</li></ul><p>Very rare side effects (seen in less than 1 to 10,000 patients)</p><ul><li>Hallucinations, disorientation, suicidal thoughts and actions</li><li>Hepatitis (inflammation of the liver)</li><li>Severe skin reaction (erythema multiforme) that may occur without warning</li></ul><p>In asthmatic patients treated with montelukast, very rare cases of a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if you get one or more of these symptoms.</p><p>Ask your doctor or pharmacist for more information about side effects. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please&nbsp;tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store below 30<sup>O</sup></li><li>Do not use this medicine after the date shown by the six numbers following EXP on the blister. The first two numbers indicate the month; the last four numbers indicate the year. This medicine expires at the end of the month shown.</li><li>Store in the original package in order to protect from light and moisture.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help tp protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Content of Pack and further Information</p><p>What Leukast chewable tablets contain is Leukast 4 mg: Each tablet contains montelukast sodium which corresponds to 4 mg of montelukast.</p><p>The other ingredients are: Mannitol; Microcrystalline Cellulose; Croscarmellose Sodium; Red Iron Oxide; Hydroxypropyl Cellulose; Purified Water; Cherry powder flavor; Aspartam; Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Leukast 4 mg chewable tablet is pink colour, oval concave tablets embossed with JI 137 on one side.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong><br />for Leukast 4 mg chewable tablets are held by<br />Jazeera Pharmaceutical Industries (JPI)<br />Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229<br />Tel.: +966-11-207-8172<br />Fax: +966-11-207-8097<br />Email: medical@jpi.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 01/2014, version 1.1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لوكاست للأطفال هو مضاد مستقبلات الليكوترين الذي يمنع مواد تسمى يوكوترين. يوكوترين يسبب تضييق وتورم الممرات الهوائية في الرئتين. من خلال منع يوكوترين، لوكاست يحسن أعراض الربو ويساعد على السيطرة على الربو.</p><p dir="RTL">يصف طبيبك لوكاست للأطفال لعلاج الربو، ومنع أعراض الربو خلال النهار والليل.</p><ul dir="rtl"><li>يستخدم لوكاست للأطفال لعلاج المرضى الذين لم التحكم بشكل كاف على الربو ويحتاجون لعلاج اضافي.</li><li>لوكاست للأطفال يمكن أيضا أن يستخدم كعلاج بديل لاستنشاق الكورتيزون للمرضى بين 6- 14 سنة الذين لم يتناولوا مؤخرا كورتيكوستيرودات عن طريق الفم لعلاج الربو، وأظهروا عدم قدرتهم على استخدام الستيرويدات المستنشقة.</li><li>يساعد لوكاست للأطفال أيضا منع تضييق المسالك التنفسية الناجمة عن ممارسة الرياضة.</li></ul><p dir="RTL">طبيبك سوف يحدد كيفية استخدام لوكاست للأطفال ينبغي أن تستخدم اعتمادا على أعراض الربو وشدتها عليك او على طفلك</p><p dir="RTL"><strong>ما هو الربو؟</strong></p><p dir="RTL">الربو هو مرض طويل الأجل.</p><p dir="RTL">الربو يشمل ما يلي:</p><ul dir="rtl"><li>صعوبة في التنفس بسبب ضيق الشعب الهوائية. ضيق التنفس هذا قد يزداد سوءا او يتحسن استجابة لظروف مختلفة.</li><li>الشعب الهوائية الحساسة تستجيب لأشياء كثيرة، مثل دخان السجائر، وحبوب اللقاح، والهواء البارد، أو ممارسة الرياضة.</li><li>تورم (الالتهاب)&nbsp;في بطانة الشعب الهوائية.</li></ul><p dir="RTL"><strong>أعراض الربو ما يلي: </strong>السعال، والصفير، وضيق الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبيبك عن أي مشاكل طبية أو حساسية لك أو لطفلك تعاني منها الان او في وقت مضى.</p><p dir="RTL"><strong>لا تأخذ لوكاست للأطفال إذا كنت أنت أو طفلك</strong></p><ul dir="rtl"><li>حساسية (الحساسية) لمونتيليوكاست أو أي من المكونات الأخرى من لوكاست للأطفال (انظر 6. للمزيد من المعلومات).</li></ul><p dir="RTL"><strong>الحذر عند استخدام لوكاست</strong></p><ul dir="rtl"><li>إذا ساءت حالة الربو او القدرة على التنفس عندك او عند طفلك، أخبر طبيبك فورا.</li><li><strong>&nbsp;</strong>لوكاست للأطفال عن طريق الفم لايعالج نوبات الربو الحادة. في حالة حدوث النوبات الحادة، اتبع الإرشادات التي قام الطبيب بإعطائك لك او لطفلك. دائما استنشق الدواء الخاص بك لنوبات الربو الحادة.</li><li>من المهم أن كنت أنت أو طفلك استخدام جميع أدوية الربو الموصوفة من قبل الطبيب. لوكاست للأطفال لا ينبغي أن تستخدم بدلا من أدوية الربو الأخرى التي وصفها الطبيب لك أو لطفلك.</li><li>يجب على المريض الذي يستخدم علاج الربو أن يكون على حذر و أن يستشير الطبيب في حال ظهور مجموعة من الاعراض مثل الأعراض الشبيهة بمرض الإنفلونزا، أو أحس بوخز أو خدر في الذراعين أو الساقين، أو تفاقمت أعراض الربو الرئوية، أوفي حال ظهور طفح جلدي.</li><li>يجب ان لا يأخذ المريض حمض أسيتيل الساليسيليك-(الأسبرين) أو الأدوية المضادة للالتهابات (المعروف أيضا باسم العقاقير المضادة للالتهاب غير الستيرويدية أو مضادات الالتهاب غير الستيروئيدية) إذ أنها تجعل الربو يزداد سوءا.</li></ul><p dir="RTL"><strong>استخدامه عند الأطفال</strong></p><p dir="RTL">للأطفال مابين 2- 5 سنوات من العمر،يتوفر لوكاست 4 ملغ أقراص قابلة للمضغ.</p><p dir="RTL">اما الأطفال مابين 6- 14 سنة، تتوفر لوكاست 5 ملغ أقراص قابلة للمضغ.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل دواء لوكاست ، أو ان دواء لوكاست قد يؤثر على كيفية عمل الأدوية الأخرى.</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت أنت أو طفلك أو اخذت مؤخرا ادوية، بما فيها تلك التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">أخبر طبيبك إذا كنت أنت أو طفلك استعملت الأدوية التالية قبل البدء باستخدام لوكاست:</p><ul dir="rtl"><li>الفينوباربيتال (التي تستخدم لعلاج الصرع)</li><li>الفينيتوين (المستخدم لعلاج الصرع)</li><li>ريفامبيسين (المستخدمة لعلاج السل وبعض الأمراض الأخرى)</li></ul><p dir="RTL"><strong>لوكاست مع الطعام والشراب</strong></p><p dir="RTL">لا ينبغي أن تؤخذ أقراص لوكاست 4 ملجم القابلة للمضغ فورا مع الطعام، بل ينبغي أن تؤخذ على الأقل بساعة قبل أو بعد ساعتين من الغذاء.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>استخدامه في الحمل</strong></p><p dir="RTL">يجب على النساء الحوامل أو من تنوي أن تصبح حاملا استشارة الطبيب قبل استعمال لوكاست. طبيبك سوف يقرر ما إذا كان يمكنك استعمال لوكاست خلال هذا الوقت.</p><p dir="RTL"><strong>استخدامه في الرضاعة الطبيعية</strong></p><p dir="RTL">من غير المعروف ظهور لوكاست في حليب الثدي. يجب استشارة الطبيب قبل تناول لوكاست إذا كنت مرضعا رضاعة طبيعية أو تنوين الإرضاع.</p><p dir="RTL"><strong>القيادة واستخدام الآليات</strong></p><p dir="RTL">ليس من المتوقع أن يؤثر لوكاست على قدرتك على قيادة السيارة أو تشغيل الآلات. ومع ذلك، قد تختلف استجابات الفرد للدواء. بعض الآثار الجانبية (مثل الدوخة والنعاس) التي تم الإبلاغ عنها نادرا جدا مع لوكاست التي قد تؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض العناصر المكونه لأقراص لوكاست</strong></p><p dir="RTL">لوكاست أقراص قابلة للمضغ تحتوي على الأسبارتام، وهي مصدر للفينيل ألانين . إذا كان طفلك لديه بيلة الفينيل كيتون (اضطراب وراثي نادر في الاستقلاب) يجب أن تأخذ في الاعتبار أن كل قرص 4 ملجم يحتوي على الفينيل ألانين (أي ما يعادل&nbsp; 0.96 &nbsp;ملجم من الفينيل ألانين).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><ul dir="rtl"><li>هذا الدواء يعطى للطفل تحت إشراف الكبار.</li><li>يجب أن يتناول طفلك حبة واحدة فقط من لوكاست للأطفال مرة واحدة يوميا على النحو الذي يحدده الطبيب.</li><li>وينبغي أن يتناول لوكاست حتى عندما يكون طفلك ليست لديه أي أعراض للربو أو إذا كانت تنتابه نوبة الربو الحادة.</li><li>تناول لوكاست كما وصفه طبيبك . يجب أن تتحقق من الطبيب او الصيدلي إذا كنت غير متأكد.</li><li>يؤخذ عن طريق الفم</li></ul><p dir="RTL">للأطفال 2- 5 سنوات من العمر:</p><p dir="RTL">تناول قرص واحد من اقراص لوكاست 4 ملجم القابلة للمضغ، لا ينبغي تناول اقراص لوكاست 4 ملجم القابلة للمضغ فورا مع الطعام، بل ينبغي أن تؤخذ على الأقل بساعة واحدة قبل الأكل أو بساعتين بعد الأكل.</p><p dir="RTL">إذا كان طفلك يستعمل اقراص لوكاست ، يجب التأكد أنه / أنها لا يأخذ أي أدوية أخرى تحتوي على نفس المادة الفعالة &quot;مونتيليوكاست&quot;.</p><p dir="RTL">للأطفال 2- 5 سنوات من العمر، تتوفر اقراص لوكاست 4 ملجم القابلة للمضغ.</p><p dir="RTL">للأطفال 6- 14 سنة، تتوفر اقراص لوكاست 5 ملجم القابلة للمضغ.</p><p dir="RTL">لا ينصح بتناول الأطفال ممن هم أقل من عمر السنتين بتناول اقراص لوكاست 4 ملجم القابلة للمضغ.</p><p dir="RTL"><strong>الجرعة الزائدة</strong></p><p dir="RTL">اذا اخذت جرعة زائدة كبيرة من لوكاست اتصل بطبيبك للحصول على المشورة الطبية، كما قد تحتاج الى عناية طبية. لم تذكر أي آثار جانبية في معظم تقارير الجرعة الزائدة. شملت الأعراض التي تحدث في أغلب الأحيان مع الجرعة الزائدة عند البالغين والأطفال : آلام في البطن، والنعاس، والعطش، والصداع، والتقيؤ، وفرط النشاط.</p><p dir="RTL"><strong>نسيان تناول جرعة لوكاست</strong></p><p dir="RTL">اذا وجدت نفسك نسيت تناول جرعتك من لوكاست، انتظر حتى وقت تناول الجرعة التالية في وقتها المعتاد.</p><p dir="RTL">لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسيه.</p><p dir="RTL">اذا كان لديك أي اسئلة اخرى عن استخدام هذا المنتج اسأل طبيب طفلك او الصيدلي.</p><p dir="RTL">التوقف عن تناول الدواء</p><p dir="RTL">تعالج اقراص لوكاست الربو عند طفلك فقط عند استمرار تناول هذه الأقراص.</p><p dir="RTL">من المهم لطفلك مواصلة تناول لوكاست للأطفال لطالما يستمر بوصفه الطبيب. اذ انه يساعد في السيطرة على الربو عند طفلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، ونطلب طبيب طفلك او الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل جميع الأدوية يمكن لهذا الدواء ان يسبب اعراضا جانبية، وان لم تحصل لجميع المرضى. في الدراسات السريرية مع أقراص لوكاست القابلة للمضغ 5 ملجم ، اظهرت ان الآثار الجانبية الأكثر شيوعا (التي تحدث عند 1 على الأقل من 100 مريض، وأقل من 1 من 10 الأطفال المرضى المعالجين) و يعتقد أن لهما صلة بأقراص لوكاست للأطفال هي:</p><ul dir="rtl"><li>صداع</li></ul><p dir="RTL">بالإضافة إلى ذلك، تم الإبلاغ عن الآثار الجانبية التالية في الدراسات السريرية مع اقراص لوكاست 10 ملجم&nbsp; المغلفة :</p><ul dir="rtl"><li>ألم في البطن</li></ul><p dir="RTL">عادة ما تكون هذه الاثار خفيفة وحصلت بشكل أكبر عند المرضى المعالجون بأقراص لوكاست بالمقارنة مع المرضى الذين عولجوا بأقراص وهمية (الأقراص المستخدمة لا تحتوي على الدواء).</p><p dir="RTL">تم الابلاغ عن الآثار الجانبية التالية خلال فترة تسويق الدواء</p><p dir="RTL">الآثار الجانبية الشائعة جدا &nbsp;(يؤثر على أكثر من 1 من كل10 شخصا)</p><ul dir="rtl"><li>عدوى الجهاز التنفسي العلوي</li></ul><p dir="RTL">الآثار الجانبية الشائعة ( يؤثر على 1- 10 مرضى في 100 ) ما يلي:</p><ul dir="rtl"><li>الاسهال، والغثيان، والتقيؤ</li><li>طفح جلدي</li><li>حمى</li></ul><p dir="RTL">الآثار الجانبية غير شائعة (يؤثر على 1- 10 مرضى في &nbsp;1000) ما يلي:</p><ul dir="rtl"><li>ردود فعل تحسسيه بما في ذلك تورم في الوجه والشفتين واللسان، و / أو الحلق مما قد يسبب صعوبة في التنفس أو البلع</li><li>&nbsp;تغييرات سلوكيه ومزاجية [حلم غير طبيعية، بما في ذلك الكوابيس، واضطرابات النوم، والمشي أثناء النوم، والتهيج، والشعور بالقلق، والأرق، والتهيج بما في ذلك السلوك العدواني أو العداء والاكتئاب</li><li>دوار، والنعاس، ووخز / تنميل، وتشنجات</li><li>النزيف الأنفي</li><li>جفاف الفم، وعسر الهضم</li><li>كدمات، والحكة، و الشرى</li><li>ألم في العضلات او المفاصل، وتشنجات العضلات</li><li>الضعف / التعب، والشعور بالإعياء، وتورم</li></ul><p dir="RTL">الآثار جانبية النادرة (يؤثر على 1- 10 مرضى في 10000 )ما يلي:</p><ul dir="rtl"><li>زيادة القابلية للنزف</li><li>ارتجاف، واضطراب في الانتباه، وضعف الذاكرة</li><li>خفقان</li></ul><p dir="RTL">الآثار الجانبية النادرة جدا (شوهدت في أقل من 1 إلى10000 من المرضى )</p><ul dir="rtl"><li>الهلوسة، والارتباك، والأفكار والأعمال الانتحارية</li><li>التهاب الكبد</li><li>رد فعل تحسسي وخيم للجلد (حمامي عديدة الأشكال) التي قد تحدث دون سابق إنذار</li></ul><p dir="RTL">في مرضى الربو الذين يعالجون بمونتيليوكاست، تم الإبلاغ عن حالات نادرة جدا عن مجموعة من الأعراض مثل الأعراض الشبيهة بمرض الإنفلونزا، أو الأحس بوخز&nbsp; أو خدر في الذراعين أو الساقين، أو تفاقمت أعراض الربو الرئوية، أوفي حال ظهور طفح جلدي (متلازمة شيرغ ستروس). يجب عليك إخبار الطبيب على الفور إذا حصلت لك واحد أو أكثر من هذه الأعراض.</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على مزيد من المعلومات حول الآثار الجانبية. إذا حصلت أي من الآثار الجانبية الخطيرة، أو إذا لاحظت أي آثار جانبية من غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>ابقي هذا المستحضر بعيدا عن متناول ايدي ونظر الأطفال.</li><li>يخزن في درجة حرارة لا تتجاوز 30 &deg; مئوية.</li><li>لاتستخدم لوكاست بعد تاريخ انتهاء الصلاحية كما هو مدون على العبوة ، تاريخ الإنتهاء يشار اليه انه اليوم الأخير من ذلك الشهر.</li><li>يحفظ الدواء في علبته الأصلية للمحافظة عليه من الضوء و الرطوبة.</li><li>إذا تغيّر لون الدواء او ظهرت عليه علامة اخرى من علامات التلف، اسأل الصيدلي الذي سوف ينصحك بما يجب القيام به.</li><li>لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي او النفايات المنزلية، اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها وذلك لأن هذه التدابير تساعد في حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">المادة الفعالة: كل قرص يحتوي على مونتيليوكاست صوديوم والتي تكافئ 4 ملجم من مونتيليوكاست.</p><p>المكونات الأخرى هي: مانيتول؛ السليلوز الجريزوفولفين ؛ كروكارمللوز الصوديوم؛ أكسيد الحديد الأحمر؛ هيدروكسي بروبيل السليلوز؛ تنقية المياه؛ الكرز مسحوق نكهة؛ اسبارتام؛ ستيرات المغنيسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>اقراص لوكاست 4 ملجم القابلة للمضغ وردية اللون، بيضاوية الشكل و مقعرة السطح نقش عليها من جهة واحدة عبارة 137JI</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجزيرة للصناعات الدوائية&nbsp; (JPI)</p><p dir="RTL">الرياض، المملكة العربية السعودية، الرياض 11666 ، صندوق البريد 106229</p><p dir="RTL">رقم الهاتف: 8172 - 207 - 11 - 966 +</p><p>فاكس: 8097 - 207 - 11 - 966 +</p><p>البريد الالكتروني: medical@jpi.com.sa<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة الأخيرة في 01 / 2014 ، رقم النسخة 1,1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Leukast® Paediatric 4 mg Chewable Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One chewable tablet contains monteLukast sodium, which is equivalent to 4 mg monteLukast. 
Excipient:  Aspartame 0.96 mg per tablet 
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet.
Pink color, oval concave tablets embossed with JI 137 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEUKAST is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &#39;as-needed&#39; short-acting &beta;-agonists provide inadequate clinical control of asthma.</p><p>LEUKAST may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p>LEUKAST is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is to be given to a child under adult supervision.The dosage for paediatric patients 2-5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, LEUKAST should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary. The LEUKAST Paediatric 4 mg chewable tablet formulation is not recommended below 2 years of age.</p><p><em>General recommendations</em>:</p><p>The therapeutic effect of LEUKAST on parameters of asthma control occurs within one day. Patients should be advised to continue taking LEUKAST even if their asthma is under control, as well as during periods of worsening asthma.</p><p>No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p>LEUKAST <em>as an alternative treatment option to low-dose inhaled corticosteroids for mild,&nbsp; persistent asthma:</em></p><p>MonteLukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of monteLukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p><em>LEUKAST as prophylaxis of asthma for 2 to 5 year old patients in whom the predominant component is exercise-induced bronchoconstriction</em>.</p><p>In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with monteLukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p><em>Therapy with </em>LEUKAST <em>in relation to other treatments for asthma.</em></p><p>When treatment with LEUKAST is used as add-on therapy to inhaled corticosteroids, LEUKAST should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p>10 mg film-coated tablets are available for adults 15 years of age and older.</p><p>5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.</p><p>4 mg chewable tablets are available for paediatric patients 2 to 5 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral monteLukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p>MonteLukast should not be abruptly substituted for inhaled or oral corticosteroids. There are no data demonstrating that oral corticosteroids can be reduced when monteLukast is given concomitantly.</p><p>In rare cases, patients on therapy with anti-asthma agents including monteLukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases usually, but not always, have been associated with the reduction or withdrawal of oral corticosteroid therapy. The possibility that leukotriene receptor antagonists may be associated with emergence of Churg-Strauss syndrome can neither be excluded nor established. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>LEUKAST contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take into account that each 4 mg chewable tablet contains phenylalanine in an amount equivalent to 0.674 mg phenylalanine per dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MonteLukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of monteLukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>The area under the plasma concentration curve (AUC) for monteLukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since monteLukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when monteLukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p><em>In vitro </em>studies have shown that monteLukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving monteLukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that monteLukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, monteLukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (eg., paclitaxel, rosiglitazone, and repaglinide).</p><p><em>In vitro </em>studies have shown that monteLukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving monteLukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of monteLukast by 4.4-fold. No routine dosage adjustment of monteLukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of monteLukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of monteLukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy Category B</strong></p><p><em>Use during pregnancy</em></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p>Limited data from available pregnancy databases do not suggest a causal relationship between LEUKAST and malformations (i.e. limb defects) that have been rarely reported in worldwide post marketing experience.</p><p>LEUKAST may be used during pregnancy only if it is considered to be clearly essential.</p><p><em>Use during lactation</em></p><p>Studies in rats have shown that monteLukast is excreted in milk (see section 5.3). It is not known if monteLukast is excreted in human milk.</p><p>LEUKAST may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MonteLukast is not expected to affect a patient&#39;s ability to drive a car or operate machinery. However, in very rare cases, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MonteLukast has been evaluated in clinical studies in patients with persistent asthma as follows:</p><ul><li><strong>&nbsp;</strong> 10 mg film-coated tablets in approximately 4,000 adult patients 15 years of age and older</li><li>&nbsp; 5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of age, and</li><li>&nbsp;4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.</li></ul><p>MonteLukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</p><ul><li>&nbsp;4 mg granules and chewable tablets in 1038 paediatric patients 6 months to 5 years of age</li></ul><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with monteLukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p><strong>Adult Patients 15 years and older</strong></p><p><strong>(two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients 6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients 2 to 5 years old</strong></p><p><strong>(one 12-week study; n=461)</strong></p><p><strong>(one 48-week study; n=278)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thirst</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p>Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with monteLukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p>Post-marketing Experience</p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Experience Term, in the table below. Frequency Categories were estimated based on relevant clinical trials.<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Experience Term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorder</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor<sup>&sect;</sup>)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disturbance in attention, memory impairment</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorder</p></td><td style="vertical-align:top"><p>dizziness, drowsiness paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Adverse Experience Term</p></td><td style="vertical-align:top"><p>Frequency Category*</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection&dagger;</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea<sup>&Dagger;</sup>, nausea<sup>&Dagger;</sup>, vomiting<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, oedema,</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received monteLukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received monteLukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p style="text-align:justify"><strong><u>Reporting of suspected adverse reactions</u></strong></p><ul><li style="text-align:justify">&nbsp;<strong>Saudi Arabia:</strong></li></ul><p style="text-align:justify">&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="text-align:justify">Fax: +966-11-205-7662</p><p style="text-align:justify">Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:justify">Toll free phone: 8002490000</p><p style="text-align:justify">E-mail: <u>npc.drug@sfda.gov.sa</u></p><p style="text-align:justify">Website:<u> www.sfda.gov.sa/npc</u></p><ul><li style="text-align:justify"><strong>Other GCC States: </strong>Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with monteLukast. In chronic asthma studies, monteLukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with monteLukast. These include reports in adults and children with a dose as high as 1000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports. The most frequently occurring adverse experiences were consistent with the safety profile of monteLukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p>It is not known whether monteLukast is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pharmacotherapeutic group: </strong>Leukotriene receptor antagonist</p><p style="text-align:justify"><strong>ATC Code: </strong>RO3D CO3</p><p style="text-align:justify">The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro- asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p style="text-align:justify">MonteLukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, monteLukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within two hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by monteLukast. Treatment with monteLukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. MonteLukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with monteLukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and paediatric patients 2 to 14 years of age, monteLukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p style="text-align:justify">In studies in adults, monteLukast 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and night-time asthma symptoms scores was significantly better than placebo.</p><p style="text-align:justify">Studies in adults demonstrated the ability of monteLukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclometasone plus monteLukast vs beclometasone, respectively for FEV1 : 5.43% vs 1.04%; &beta;-agonist use: - 8.70% vs 2.64%). Compared with inhaled beclometasone (200 &mu;g twice daily with a spacer device), monteLukast demonstrated a more rapid initial response, although over the 12-week study, beclometasone provided a greater average treatment effect (% change from baseline for monteLukast vs beclometasone, respectively for FEV1 : 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclometasone, a high percentage of patients treated with monteLukast achieved similar clinical responses (e.g. 50% of patients treated with beclometasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately 42% of patients treated with monteLukast achieved the same response).</p><p style="text-align:justify">In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, monteLukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulised corticosteroids or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. MonteLukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and night-time symptoms compared with placebo. MonteLukast also decreased &#39;as needed&#39; &beta;-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving monteLukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p style="text-align:justify">In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, monteLukast 4 mg once daily significantly (p&le; 0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge; 3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalisation for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p style="text-align:justify">In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with monteLukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with monteLukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p style="text-align:justify">In an 8-week study in paediatric patients 6 to 14 years of age, monteLukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &#39;as-needed&#39; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p style="text-align:justify">In a 12-month study comparing the efficacy of monteLukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma, monteLukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the monteLukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both monteLukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:</p><ul><li style="text-align:justify">FEV1 increased from 1.83 L to 2.09 L in the monteLukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV1 was -0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV1 was 0.6% in the monteLukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV1 was significant: -2.2% with a 95% CI of -3.6, -0.7.</li><li style="text-align:justify">The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the monteLukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</li><li style="text-align:justify">The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the monteLukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</li><li style="text-align:justify">The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the monteLukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</li></ul><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV1 22.33% for monteLukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients 6 to 14 years of age (maximal fall in FEV1 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with monteLukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption: </em>MonteLukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved three hours (T<sub>max)</sub> after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C<sub>max </sub>are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film- coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the C<sub>max</sub> is achieved in two hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p>After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, C<sub>max </sub>is achieved 2 hours after administration. The mean C<sub>max</sub> is 66% higher while mean C<sub>min</sub> is lower than in adults receiving a 10 mg tablet.</p><p><em>Distribution: </em>MonteLukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of monteLukast averages 8-11 litres. Studies in rats with radiolabelled monteLukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p><em>Biotransformation: </em>MonteLukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of monteLukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of monteLukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of monteLukast in healthy subjects that received 10 mg monteLukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of monteLukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of monteLukast is minimal.</p><p><em>Elimination</em>: The plasma clearance of monteLukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled monteLukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of monteLukast oral bioavailability, this indicates that monteLukast and its metabolites are excreted almost exclusively <em>via </em>the bile.</p><p><em>Characteristics in patients: </em>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because monteLukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of monteLukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>With high doses of monteLukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure<strong> </strong>seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day ( &gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, monteLukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day ( &gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. MonteLukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>No deaths occurred following a single oral administration of monteLukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively) the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>MonteLukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>MonteLukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><ul><li>Mannitol</li><li>Microcrystalline Cellulose</li><li>Croscarmellose Sodium</li><li>Red Iron Oxide</li><li>Hydroxypropyl cellulose LF</li><li>Purified&nbsp; Water</li><li>Cherry powder flavor</li><li>Aspartam</li><li>Magnesium Stearate<br />&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in Aluminum/aluminium blisters</p><p>Pack size: 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI)
Riyadh, Saudi Arabia
11666 Riyadh, P.O.Box 106229
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 January 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>